8 November 2023 - Novo Nordisk said on Wednesday it would discontinue its long-acting insulin Levemir in the United States, citing manufacturing constraints, reduced patient access and available alternatives.

The Danish drug maker said supply disruptions would start in mid January, followed by discontinuation of the Levemir injection pen in April and of Levemir vials by the end of 2024.

Read Reuters article